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Objective: Cardiovascular disease (CVD) occurs frequently and may progress more rapidly in overt
hypothyroidism (OVH). However, the role of mild thyroid failure as a risk factor for CVD is not clear.
This study is aimed at exploring the association between subclinical hypothyroidism (SCH) and coronary
artery disease (CAD), as detected by cardiac computed tomography (CT), in apparently healthy subjects.
Subjects andmethods: We retrospectively enrolled 2404 asymptomatic subjects who underwent cardiac CT
with an intermediate to high risk (Framingham 10-year risk R10%) of developing CAD but with no
known CAD or thyroid disease. Coronary artery calcium score (CACS) was assessed by calcium scan, and
the presence of the plaques (CAD), withR50% stenosis being indicative of obstructive CAD, was assessed
by coronary CT angiography.
Results: Of the 2404 subjects, 2355 subjects were euthyroid (Eu; 53G9 years, 83 females) and 49 had SCH
(58G12 years, seven females). CAD and CACSO100 were more prevalent in SCH subjects than in Eu
subjects (Eu vs SCH: CAD, 948 (40.6%) vs 31 (63.3%), PZ0.002; CACS O100, 239 (10.3%) vs 10
(20.4%), PZ0.031). SCH was also an independent risk factor for CAD after a multivariate analysis
(odds ratio: 2.125, 95% confidence interval: 1.049–4.307, PZ0.036).
Conclusions: SCH subjects who were at an intermediate-to-high risk of developing CAD were significantly
more likely to exhibit occult CAD than Eu subjects, especially in men with SCH. These findings suggest that
mild thyroid failure also independently contributes to the development of CAD.
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The cardiovascular system is a major target of thyroid
hormone action (1, 2). Changes in thyroid function
result in several alterations in cardiac hemodynamics.
Overt hypothyroidism (OVH) has been known to
accelerate the development of coronary atherosclerosis.
Small-scaled case–control and cohort studies have
shown that coronary atherosclerosis in subjects with
hypothyroidism is more frequent and severe than in
normal subjects (3). There is substantial evidence that
OVH alters the traditional risk factors for cardiovascular
disease (CVD) by increasing the circulating levels of
atherogenic low-density lipoprotein cholesterol (LDL-C)
particles, inducing systolic/diastolic hypertension and
abnormalities in coagulation and increasing plasma
homocysteine and C-reactive protein levels (1–8).
Subclinical hypothyroidism (SCH) is characterized by
elevated serum TSH levels with normal concentrations
of free thyroxine (fT4) (9). The rate of detection of SCH isndocrinologymarkedly increasing due to the rise in routine screening
procedures. However, the contribution of SCH to the
future development of atherosclerosis is still being debated.
X-ray coronary angiography is still the gold standard
for the diagnosis of coronary artery disease (CAD), but
it has some limitations due to its invasive nature. Recent
advancements in the multidetector technology of com-
puted tomography (CT) have allowed physicians to
explore coronary artery anatomy in a noninvasive manner
(10, 11). Coronary artery calcium score (CACS) has
already been accepted as an effective prognostic indicator
of CAD that is independent of traditional risk factors
(12–14). Coronary CT angiography (cCTA) can provide
comprehensive information regarding the location,
severity, and characteristics of atherosclerotic plaques.
Bachar et al. (15) reported that occult CAD is
common in asymptomatic patients with a risk profile
for CAD and that in about 5% of patients at clinical risk,
cCTA can detect obstructive CAD that mandates further
investigation. Hadamitzky et al. (16) demonstrated theDOI: 10.1530/EJE-11-0014
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including unstable angina and late revascularization
(O90 days after the index visit), in asymptomatic
patients who had high cardiovascular risk profiles.
In this study, we, therefore, investigated the incidence of
atherosclerotic CAD, as detected by cardiac CT, in asymp-
tomatic subjects with intermediate-to-high risk profiles
according to the thyroid function and explored the
relationship between mild thyroid failure and occult CAD.Subjects and methods
Study population
The medical records of consecutive asymptomatic
subjects without known CAD who underwent a cardiac
CT evaluation as part of his or her self-referred health
checkup at the Seoul National University Bundang
Hospital (SNUBH) Health Promotion Center between
December 2005 and November 2008 were reviewed.
Among these, 2404 who met the inclusion criteria (i)
euthyroidism (Eu) or SCH and ii) intermediate-to-high
risk of developing CVD based on the Framingham risk
predictor model (Framingham 10-year risk R10%))
were included in our analysis; 2355 subjects were Eu
(2272 males and 83 females) and 49 were SCH
(42 males and seven females).
The Institutional Review Board of the SNUBH
approved the study protocol. All of the subjects were
fully informed regarding our study protocol and
participation, and either the subjects or their legal
guardians provided written informed consent.Measurement of anthropometric and
biochemical parameters
A medical history of CAD, including myocardial
infarction or angina, hypertension, diabetes mellitus,
dyslipidemia, stroke, a family history of premature CAD,
a current medication profile, and smoking status, was
systematically acquired. Height (cm) and body weight
(kg) were measured to the nearest 0.1 cm and 0.1 kg
respectively. During the height and weight measure-
ments, the subjects were barefoot and wearing light
clothing. Body mass index was calculated by dividing
weight by the height squared (kg/m2). Waist circum-
ference was measured to the nearest 0.1 cm at the
narrowest point between the lower limit of the ribcage
and the iliac crest. Blood pressure was recorded three
times after subjects had been in a relaxed state for at
least 10 min and with 5 min of rest between measure-
ments. The subjects were asked to refrain from smoking
for 24 h and from consuming alcohol for 7 days before
blood sampling. After a 14 h overnight fasting, venous
blood samples were drawn from the antecubital vein.
Plasma was separated immediately by centrifugation
(538 g, 20 min, at 4 8C), and biochemical analyses werewww.eje-online.orgconducted immediately. The fasting plasma concen-
trations of glucose, HbA1c, total cholesterol (TC),
triglyceride, high-density lipoprotein cholesterol (HDL-
C), and LDL-C were measured enzymatically using the
Hitachi 747 chemistry analyzer (Hitachi).
The serum fT4 and TSH levels were determined by
a chemiluminescence immunoassay using a commer-
cially available kit (Architect, Abbott). The reference
ranges of fT4 and TSH were 0.7–1.5 ng/dl and
0.4–4.9 mU/l respectively. The 10-year Framingham
risk score (FRS), a point system based on age, sex,
systolic blood pressure, TC, HDL-C, and smoking, was
calculated according to the NCEP guidelines (17, 18).Cardiac CT: CACS and cCTA
Patients with heart rates O70 beats per minute
received 10–30 mg of intravenous esmolol (Jeil
Pharm. Co., Ltd, Seoul, Korea) prior to cardiac CT
imaging. Cardiac CT was performed using a 64-slice
multidetector CT scanner (Brilliance 64; Philips Medical
Systems, Best, The Netherlands).
Before cCTA, a nonenhanced prospective ECG-gated
sequential scan was performed to measure CACS with
the following parameters: section collimation, 40!
0.625 mm; rotation time, 420 msec; tube voltage,
120 kV; and tube current, 55 mA. cCTA was thereafter
performed on the patients using retrospective ECG
gating with ECG-based tube current modulation and
the following parameters: rotating time, 420 msec;
tube voltage, 120 kV; effective tube current–time
product, 800 mAs; table feed per scan, 3.8 mm; and
pitch, 0.2. A bolus of 80 ml of iomeprol (Iomeron 400;
Bracco, Milan, Italy) was injected i.v. (4 ml/s) followed
by a 50 ml saline chaser. A region of interest was placed
on the descending thoracic aorta, and image acquisition
was automatically initiated once a selected threshold
(150 Hounsfield units) had been reached using bolus
tracking. Each patient’s ECG was simultaneously
recorded to allow for retrospective, segmental data
reconstruction. The images were initially recon-
structed during the mid-diastolic phase (75% of R–R
interval) of the cardiac cycle. Additional reconstructions
were performed if motion artifacts were present. The
mean radiation exposure from the cardiac CT was
13.21G0.82 mSv (13.21G0.83 for men and 13.33
G0.79 for women).
All of the scans were independently analyzed using
the 3D workstation (Brilliance; Philips Medical Systems)
by two experienced investigators who were blinded to
the clinical information. After making independent
evaluations, a consensus interpretation was used to
make a final diagnosis.
CACS were measured using a scoring system
previously described by Agatston et al. (19). Based on
the CACS, participants were categorized in the following
manner: no plaques, 0; mild plaques, 0.1–100; and
moderate to severe plaques,O100 (19, 20).
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examined using maximum intensity projection and
multiplanar reconstruction techniques on the short axis
and along multiple longitudinal axes. The lesions were
classified according to the maximal luminal diameter of
a stenosis observed on any plane. The image quality
was evaluated on a per-segment basis and classified as
good (no artifacts), adequate (the presence of image-
degrading artifacts, but feasible for evaluation with
moderate confidence), or poor (the presence of image-
degrading artifacts and feasible for evaluation only with
low confidence). The contrast-enhanced portion of the
coronary lumen was semi-automatically traced at the
maximal stenotic site and compared with the mean
values of the proximal and distal reference sites. If the
image was of adequate or poor quality, the coronary
segments were visually scored for the grading of
coronary artery stenosis.
We used the presence of any plaques (CAD),
obstructive CAD (stenosis R50%), and CACS O100
as surrogate markers of CAD.Statistical analysis
The continuous variables are expressed as the mean
GS.D., whereas the categorical variables are presented as
absolute values and percentages. The unpaired Student’s
t-test was used to test for differences in normally
distributed continuous variables and Mann–Whitney
U test was used for comparisons involving variables that
were not normally distributed. Categorical variables wereTable 1 Comparison of clinical and biochemical characteristics accor
Total
Eu (nZ2355) SCHypo (nZ49) Eu (n
TSH (mIU/l) 1.62G0.87 7.52G3.12* 1.6
Free T4 (ng/dl) 1.09G0.14 1.02G0.14* 1.0
Age (years) 53G9 58G12* 5
Female 83 (3.5) 7 (14.3)*
Smoking 2087 (91.9) 37 (86.0) 207
Hypertension 764 (32.4) 19 (38.8) 727
Diabetes 314 (13.3) 8 (16.3) 306
Hypercholesterolemia 1661 (70.5) 35 (71.4) 160
FHx of CAD 283 (17.9) 5 (15.2) 269
Hx of stroke 26 (1.7) 0 (0.0) 26
WC (cm) 88.7G7.4 87.6G7.9 88.
BMI (kg/m2) 25.8G4.1 25.1G3.7 25.
SBP (mmHg) 122G15 124G17 12
DBP (mmHg) 77G11 76G10 7
FBS (mg/dl) 99G26 98G16 9
HbA1c (%) 5.9G0.9 5.9G0.6 5.
TC (mg/dl) 214G36 214G36 21
LDL-C (mg/dl) 119G27 118G30 11
HDL-C (mg/dl) 49G11 52G14 4
TG (mg/dl) 164G108 158G76 16
10-year FRS (%) 14.5G4.7 15.6G6.2 14.
*P value!0.05 when compared with euthyroid group. Eu, euthyroid; SCH, subc
past medical history; WC, waist circumference; BMI, body mass index; SBP,
glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; LDL-C, low-dens
triglyceride; 10-year FRS, 10-year Framingham risk score; N/A, not applicable.compared with the c2 test or Fisher’s exact test as
appropriate. Multivariate and logistic regression analysis
was employed to identify independent predictors of CAD,
obstructive CAD, and CACSO100. A P value!0.05 was
considered statistically significant, and all analyses were
performed using the SPSS 15.0 statistical package (SPSS,
Inc., Chicago, IL, USA).Results
Baseline characteristics according to thyroid
functional status
Among the 2404 subjects, the numbers of Eu and SCH
subjects were 2355 and 49 respectively. The compari-
son of their clinical and biochemical characteristics is
shown in Table 1.
The SCH group included more females and older
subjects than the Eu group (the number of female, Eu
versus SCH, 83 (3.5%) vs 7 (14.3%), P!0.005; age, Eu
versus SCH, 53G9 vs 58G12, P!0.005). The subjects’
history of diabetes, hypertension, hypercholesterolemia,
and smoking was similar. There were no differences in
clinical and biochemical characteristics between the Eu
and the SCH groups. There were also no differences in
10-year FRS between the two groups (14.5G4.7 vs
15.6G6.2, PZ0.373).
Because the male gender is a very strong coronary
risk factor, we also compared the characteristics of the
subjects according to gender. The basal characteristics
of the two groups were more similar when analyzedding to the thyroid function and sex.
Male Female
Z2272) SCHypo (nZ42) Eu (nZ83) SCHypo (nZ7)
0G0.86 7.70G3.30* 2.05G0.94 6.44G1.30*
9G0.14 1.02G0.14* 1.07G0.15 0.98G0.13
3G9 58G12* 57G13 63G14
N/A N/A N/A N/A
5 (92.6) 36 (90.0) 12 (40.0) 1 (33.3)
(32.0) 17 (40.5) 37 (44.6) 2 (28.6)
(13.5) 7 (16.7) 8 (9.6) 1 (14.3)
5 (70.6) 29 (69.0) 56 (67.5) 6 (85.7)
(17.9) 5 (17.9) 14 (18.7) 0 (0.0)
(1.8) 0 (0.0) 0 (0.0) 0 (0.0)
9G7.2 88.1G7.7 83.6G9.7 84.9G8.6
9G4.0 25.8G3.4 21.3G3.9 21.2G3.3
2G15 124G15 125G22 124G28
7G11 77G10 71G11 70G7
9G26 98G15 96G32 97G19
9G0.9 5.9G0.6 5.9G1.3 6.0G0.5
4G35 211G34 211G44 234G43
9G27 116G30 114G32 127G33
9G11 50G12 57G14 60G19
6G105 159G72 130G165 148G100
5G4.7 15.6G6.3 12.0G1.8 14.7G6.4
linical hypothyroidism; FHx, family history; CAD, coronary artery disease; Hx,
systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood
ity lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG,
www.eje-online.org
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.A comparison of the incidence of CAD
according to thyroid functional status
Table 2 shows the comparison of the subjects’ cardiac
CT findings. The CACSs (mean (range)) were higher in
the SCH group (45.3 (0–2836.7) vs 141.5 (0–4582),
PZ0.015). The incidences of CAD and CACS O100
were also higher in males with SCH (CAD, Eu versus
SCH, 948 (40.6%) vs 31 (63.3%), P!0.005; CACS
O100, 232 (10.3%) vs 10 (20.4%), PZ0.031). The
differences in CAD incidences remained after adjusting
for age (whole group, odds ratio (OR) 1.935, 95%
confidence interval (CI): 1.021–3.668, PZ0.021; male,
OR 1.086, 95% CI: 1.075–1.097, PZ0.024). However,
we did not observe a difference in incidence of
obstructive CAD between the two groups because of
the limited number of SCH subjects (nZ42, Table 2) and
the low incidence of obstructive CAD itself.
In the female subjects, the incidence of CAD was
slightly higher in the SCH group compared with the Eu
group (Eu versus SCH: 17 (20.5%) vs 4 (57.1%),
PZ0.049), but this difference was barely significant
and disappeared after adjustment for age. We studied
only seven SCH subjects; therefore, a larger sample size
is warranted.
When we explored the relationship between CACS
and TSH and fT4, TSH and CACS had significant
correlation (rZ0.053, PZ0.009) but fT4 was not
related to CACS (rZK0.13, PZ0.535). We could get
similar findings in male (CACS and fT4, rZK0.021,
PZ0.320; CACS and TSH, rZ0.059, PZ0.005) but
could not in female subjects (CACS and fT4, rZ0.175,
PZ0.099; CACS and TSH, rZK0.005, PZ0.965),
maybe due to limited subject number.T
a
b
le
2
C
o
m
p
a
ri
s
o
n
o
f
C
T
A
fi
n
d
in
g
s
o
f
th
e
s
u
b
je
c
ts
a
c
c
o
rd
in
g
T
o
ta
l
E
u
(n
Z
2
3
5
5
)
S
C
H
(n
Z
4
9
)
P
C
A
C
S
4
5
.3
(0
–
2
8
3
6
.7
)
1
4
1
.5
(0
–
4
5
8
2
.9
)
0
.0
1
5
C
A
C
S
O
1
0
0
2
3
9
(1
0
.3
)
1
0
(2
0
.4
)
0
.0
3
1
C
A
D
9
4
8
(4
0
.6
)
3
1
(6
3
.3
)
0
.0
0
2
O
b
s
t.
C
A
D
8
8
(3
.8
)
2
(4
.1
)
0
.7
0
9
E
u
,
e
u
th
y
ro
id
;
S
C
H
,
s
u
b
c
lin
ic
a
l
h
y
p
o
th
y
ro
id
is
m
;
C
A
C
S
,
c
o
ro
n
a
ry
a
rt
e
ryMultivariate analysis of the relative risk
of CAD
We performed a multivariate analysis to identify risk
factors that relate to SCH. After the multivariate
analysis, known cardiovascular risk factors, such as
age, male gender, high blood pressure, high fasting
blood glucose levels, and hypercholesterolemia, were
also significant risk factors for CAD, obstructive CAD,
or CACSO100 (Table 3). SCH was an independent risk
factor for CAD (OR 2.125, 95% CI: 1.049–4.307,
PZ0.036) but not for CACS O100 and obstructive
CAD (CACS O100, OR 0.821, 95% CI: 0.186–3.614,
PZ0.794; obstructive CAD, OR 1.162, 95% CI:
0.499–2.703, PZ0.727).
We also tried to perform a subgroup analysis because
several of the factors, such as age, sex, and TSH
levels, could have been confounding. However, further
subanalyses showed no significant relationship betweenwww.eje-online.org
Table 3 Relative risks in the presence of CAD, obstructive CAD, and CACSO100.
CAD Obstructive CAD CACSO100
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age 1.094 (1.081–1.107) 0.000 1.058 (1.032–1.085) 0.000 1.116 (1.097–1.136) 0.000
Male gender 3.724 (1.645–8.429) 0.002 2.498 (0.310–20.162) 0.390 1.989 (0.715–5.528) 0.188
Smoking 1.324 (0.935–1.876) 0.114 1.239 (0.594–2.582) 0.568 1.501 (0.955–2.360) 0.078
SBP 1.009 (1.003–1.015) 0.004 1.000 (0.985–1.015) 0.996 1.002 (0.992–1.011) 0.725
FBS 3.193 (2.046–4.985) 0.000 2.206 (0.864–5.637) 0.098 3.869 (2.118–7.067) 0.000
BMI 1.001 (0.977–1.026) 0.911 0.957 (0.898–1.019) 0.172 1.045 (1.005–1.086) 0.025
LDL-C 1.006 (1.002–1.009) 0.001 1.000 (0.992–1.008) 0.946 0.999 (0.994–1.004) 0.664
HDL-C 0.992 (0.984–1.000) 0.054 0.969 (0.947–0.991) 0.005 1.000 (0.988–1.012) 0.992
SCH 2.125 (1.049–4.307) 0.036 0.821 (0.186–3.614) 0.794 1.162 (0.499–2.703) 0.727
CAD, coronary artery disease; CACS, coronary artery calcium score; OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; FBS, fasting blood
glucose; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SCH, subclinical hypothyroidism.
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or old subjects (R65 years) (data not shown). We could
not analyze the influence of the female gender due to
small number.Discussion
We compared the incidence of CAD in subjects with
intermediate-to-high risk profiles according to thyroid
function. The incidence of CAD was relatively high in
apparently healthy people (40.7%) and significantly
higher in the SCH subjects (63.3%) than in the Eu
subjects (40.6%).
The relationship between CAD and OVH is well
known. In patients with OVH, CAD frequently occurs
and may progress more rapidly by several mechanisms.
OVH increases arterial stiffness and systemic vascular
resistance, which results in higher blood pressure (8).
Dyslipidemia, especially a marked increase in LDL-C
levels, is a well-known characteristic of OVH (4), and
elevated LDL-C levels increase arterial stiffness and
atherogenicity (6). Diastolic hypertension can also
increase cardiovascular risk (5). In addition, the
relatively lower thyroid hormone levels of patients
with OVH may amplify the cardiovascular risks
associated with insulin resistance, although hypothy-
roidism itself does not cause insulin resistance directly
(21). Through these complex mechanisms, OVH is
thought to accelerate the development of coronary
atherosclerosis (1).
SCH is a very prevalent condition affecting around 4%
of the general population and 10–15% of the older
population (22). In our study, the overall incidence
of SCH was 2.0% (49/2, 404), which was relatively
low because most of our selected subjects were male.
The incidence of SCH was 1.8% (42/2, 314) and 7.8%
(7/90) in males and females respectively.
However, the association between SCH and CAD is
still somewhat controversial (23–27). The Busselton
Health Study reported that SCH is an independent risk
factor for coronary heart disease (26). Also, severalstudies have shown an association between SCH and
either specific age ranges or TSH levels. The Rotterdam
Study (23) showed a higher prevalence of atherosclero-
tic CVD in female SCH patients who were 55 years of age
or older. However, Ochs et al. (27) found in their meta-
analysis using population-based cohort studies that the
relative risk of SCH for CAD was significantly higher in
subjects younger than 65 years, but not in subjects of
age 65 years and older. Razvi et al. (28) also reported
results from a meta-analysis showing that SCH is
associated with increased CAD in subjects from younger
populations only. The degree of SCH could be another
important factor. SCH subjects with a TSH R10 mU/l
may also have an increased CAD risk, and recent data
have shown that SCH is associated with an increased
risk of CAD events and CAD mortality (27, 29).
In addition, the Wickham survey, a large-scale, long-
term follow-up study, found no evidence to suggest that
SCH is associated with an increased risk of ischemic
heart disease (IHD) (30). These discrepancies may have
originated from the heterogeneity of the study subjects
with regard to age and sex distribution, number, and the
characteristics of the selected subjects, such as inpatient
or community setting. In this study, we included only
subjects with intermediate-to-high risk profiles (10-year
FRS R10%) who would have benefitted from further
examinations to facilitate risk stratification in our
assessment of the relationship between SCH and CAD.
We found that SCH increased the risk of occult CAD in
the subjects with increased coronary risk.
In our study, we performed cardiac CT evaluations to
detect CAD. CACS has already been accepted as an
effective prognostic indicator of CAD that is independent
of traditional risk factors (12–14). Although the
diagnostic accuracy of cCTA has been reported in
many studies, its practical value to predict clinical
events is less defined (31). However, Russo et al. (32)
recently reported that CACS and cCTA findings, such as
obstructive CAD and presence of noncalcified or mixed
plaques, were predictors of a coronary event. In this
study, 60% of the study subjects were asymptomatic
and about 70% were classified as intermediate risk.www.eje-online.org
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findings on cCTA, major adverse cardiovascular events
(MACE) were extremely rare, and future MACE
incrementally increased with increasing CAD in
patients with abnormal cCTA findings. Therefore, the
presence of CAD on cCTA may be a very sensitive and
useful marker for predicting MACE in asymptomatic
subjects.
In our study subjects, the presence of CAD,
representative of the presence of occult CAD, was
significantly associated with SCH (Tables 2 and 3).
The fact that, even after adjustment for CVD risk factors
(including the male gender, which is the strongest risk
factor for CAD), SCH was still significantly associated
with the presence of CAD suggests that even mild
thyroid failure may influence the occurrence of occult
CAD and can be a useful marker to predict future MACE,
as reported by Hulten et al. (33).
In a recent paper, Razvi et al. (34) reported data from
a Wickham Reanalysis. They showed that there was
an association between IHD and IHD-related mortality
in patients with SCH over 20 years of follow-up, which is
in contrast to the data from the original Wickham
survey report (30). These results could also support
our study results showing an association between SCH
and occult CAD.
Although this study failed to identify an associa-
tion between SCH and either obstructive CAD or CACS
O100 (Tables 2 and 3), this may be due to the very
low prevalence of obstructive CAD itself. Further studies
with more subjects are needed to draw any definitive
conclusions.
In females, the presence of CAD was not associated
with SCH most likely because the number of females
included in the study was too small.
Our study included only one individual with TSH
levelsO10 mU/l, and there were only four subjects with
TSH levels O7 mU/l. Therefore, we could not compare
the group with higher TSH levels with the others
because there were not enough patients with SCH to
draw any conclusions.
Our study had some limitations including the retro-
spective design, the lack of information about the
duration of the thyroid dysfunction, and the lack of
data pertaining to serum autoantibodies and free
triiodothyronine. Because patents were self-referred for
cardiac CT, selection bias may limit the generalizabilitly
of the clinical characteristics of this cohort to the
overall SCH population. Also we could not evaluate the
association between SCH and CAD risk in subjects with
a low-risk profile of CAD, and we, therefore, cannot
extend our results to healthy subjects without risk
factors at this moment. Furthermore, regarding the
radiation exposure and lack of cost-effectiveness and
outcome data, we cannot recommend cardiac CT
evaluation in asymptomatic subjects even if at inter-
mediate-to-high CAD risk (35). However, our study
is the first report examining the association betweenwww.eje-online.orgSCH and CAD using cardiac CT, which is a very accurate
and sensitive method for detecting CAD in a noninvasive
manner.
In summary, this study suggests that subclinical
hypothyroidism is an independent risk factor for
coronary artery disease in apparently healthy subjects.
The risk of occult CAD is increased in SCH subjects who
have an increased clinical CAD risk. Thus, we can
speculate that T4 replacement may be beneficial for SCH
subjects with increased coronary risk, although a
further large-scale prospective study is needed to clarify
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